DBV Technologies S.A.
DBV.PA
Euronext Paris2.78
EUR
-0.12
- -
DBV Technologies S.A.
DBV.PA
(Euronext Paris)
Recent
price
2.78
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- DBV Technologies S.A. is a global clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative immunotherapies for food allergies and other immunological diseases. The company primarily develops and markets the Viaskin® technology platform, an epicutaneous immunotherapy patch that delivers allergens through the skin to safely desensitize patients. Its lead product candidate, Viaskin® Peanut, is designed to treat peanut allergies in children by enabling gradual immune system desensitization. DBV Technologies also explores applications of its Viaskin® technology to other food allergies such as cow's milk allergy. Founded by pediatricians with a mission to treat food allergies safely and effectively, DBV Technologies operates globally with headquarters in Châtillon, France. The company targets markets including pediatric and adult patients with allergies, focusing on immunotherapy innovation. Recently, DBV Technologies secured up to $306.9 million in a private placement financing in 2025 to advance Viaskin® Peanut through a Biologics License Application submission and prepare for a potential commercial launch in the U.S. if regulatory approval is granted. In October 2025, DBV Technologies announced the sale of approximately $30 million of American Depositary Shares (ADS) through an at-the-market offering program on Nasdaq to support working capital and corporate purposes. The company is progressing clinical trials for Viaskin® Peanut for toddlers aged 1–3 years, targeting a Biologics License Application filing under an Accelerated Approval Pathway in the second half of 2026. DBV also participates actively in scientific meetings and industry events to present study results and advance its product pipeline. The company maintains strategic investor relationships and continues to develop its immunotherapy platform to address significant unmet medical needs in allergy treatment. DBV Technologies is advancing the first epicutaneous immunotherapy to transform allergy treatment, aiming to improve patient safety and quality of life through novel immunotherapy solutions targeting food allergies with Viaskin® patches as its core product and technology offering. Its recent focus on financing, clinical progress, and regulatory planning underscores its transition toward potential commercialization and global market expansion.
Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight